A novel BTK inhibitor BGB-3111: new data presented at ASH 2017

Constantine Tam

Constantine Tam, MD, from the Peter MacCallum Cancer Centre, Melbourne, Australia tells us about a novel BTK inhibitor, BGB-3111 and how it might compare with existing treatments, such as ibrutinib. Results from three studies on the agent were presented at the ASH 2017 meeting in Atlanta, GA, and Constantine gives us a summary of the data.

Share this video  
Similar topics
Related videos
1:13
Have novel drugs made stem cell transplantation obsolete?
David Maloney
2:33
Novel BTK inhibitors for Waldenström’s macroglobulinemia
Ramon Garcia-Sanz
2:40
ERIC: current research and initiatives in CLL
Paolo Ghia
2:40
Understanding biosimilars
Bertrand Coiffier
3:36
The real cost of hematological cancer care explained
Martin Fey
Chronic Lymphocytic Leukemia
BGB-3111, Zanubrutinib
ASH 2017
Interview
More from Constantine Tam
First results from Bgb-3111 in CLL and Waldenström’s macroglobulinemia
New therapeutic targets in CLL: ROR1
Next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals